Navigation Links
FDA Approves New Dosage Strength for INTELENCE®
Date:1/3/2011

TITUSVILLE, N.J., Jan. 3, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.  

The recommended oral dose of INTELENCE tablets is 200 mg (one 200 mg tablet or two 100 mg tablets) taken twice daily following a meal. The new 200 mg product formulation is expected to launch in the U.S. later this month, and the 100 mg tablet will remain available. Patients who are unable to swallow INTELENCE tablets whole may disperse the tablets in a glass of water.

The FDA granted accelerated approval to INTELENCE in January 2008, and it has since been approved in more than 65 countries. INTELENCE received traditional FDA approval in November 2009, based on 48-week data from the DUET-1 and DUET-2 studies, and is currently marketed in the U.S. by Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P.

INTELENCE IndicationINTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in ARV treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to an NNRTI and other ARV agents. This indication is based on Week 48 analyses from two randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class ARV (NNRTI, N[t]RTI, PI) treatment-experienced adults.

The following points should be considered when initiating therapy with INTELENCE:

  • Treatment history and, when available, resistance testing, should guide the use of INTELENCE.
  • The use of other active ARV agents with INTELENCE is associated with an increased likelihood of treat
    '/>"/>

  • SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... Ill., July 30, 2014  Hospira, Inc. (NYSE: ... of injectable drugs and infusion technologies, today reported ... 2014. Net sales for the quarter were $1.1 ... $0.72. (Adjusted* measures exclude specified items as described ... schedules.) On a U.S. Generally Accepted Accounting Principles ...
    (Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
    (Date:7/29/2014)... NEW YORK , July 29, 2014 /PRNewswire-iReach/ ... on the basis of products, methods, applications, end ... register highest growth in the microbial identification market. ... in consumable costs (per test) and the time ... accuracy and continuous technological advancements. Furthermore, genotypic methods ...
    Breaking Medicine Technology:Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5
    ... 5, 2007 - Australian,biotechnology company Avexa (ASX:AVX) announced ... which,represents the first 24 week segment of its ... open-label section of the,trial (weeks 24 to 48) ... day as part of their daily treatment regime.,The ...
    ... Primary endpoint achieved -- , LAINATE, Italy - ... today positive preliminary results from its,phase II/III study ... is a broad spectrum, semi-synthetic,antibiotic that is not ... of Cosmo's MMX(tm) technology, which delivers the active,ingredient ...
    Cached Medicine Technology:Avexa's Apricitabine Clinical Trial Update 2Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III,Data with Rifamycin MMX in Infectious Diarrhea 2
    (Date:7/30/2014)... Dennis Thompson HealthDay Reporter ... fruits and vegetables are vital to good health and a ... hit five servings of fruits and vegetables each day, additional ... review suggests. The human body may only be able ... every day, limiting its ability to absorb important nutrients from ...
    (Date:7/30/2014)... FL (PRWEB) July 30, 2014 ... doctoral candidate Renee Gordon and biochemistry professor Ngozi ... to conduct research as Fulbright Scholars. The prestigious ... education exchange program that awards grants to students, ... and conduct research abroad. Both Gordon and Ugochukwu ...
    (Date:7/30/2014)... BuyCBDOnline.co , the web's leading ... to announce that it is has made available through ... products available for immediate shipping. , "We have to ... stages," site founder Jason Liss says. "For being such ... of unique products that are available or will be ...
    (Date:7/30/2014)... July 30, 2014 The Independent ... will be holding 5 free financial workshops in the ... The goal of these workshops is our collective ... heights of financial empowerment. , These workshops were designed ... Kiyosaki, a successful investor, entrepreneur, and bestselling author (Rich ...
    (Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Chinese in ...
    Breaking Medicine News(10 mins):Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 2Health News:Fruits, Veggies May Have Their Limits in Boosting Lifespan 3Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 2Health News:FAMU Professor and Engineering Student Named Fulbright Scholars 3Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 2Health News:Delicious, Unique CBD-Rich Hemp Oil Product Debuts from BuyCBDOnline.co 3Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 2Health News:The Independent Woman is Coming to the San Francisco Area in August - Women Helping Women Reach Their Financial Goals 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4
    ... Cutting out a can per day brought measurable benefits, study ... small reduction per day in sweetened soft drink intake could ... study, researchers found a measurable reduction in blood pressure -- ... 120/80 desired reading, and 1.1 points in diastolic pressure -- ...
    ... ... ... 2010 -- Prize4Life ( www.prize4life.org ), a nonprofit organization founded to accelerate the discovery of ... gala and charity auction at the Roger Smith Hotel on Thursday, May 27. The auction ...
    ... ... serving patients, healthcare providers and payers in region. , ... Philadelphia, PA (PRWEB) May 10, ... infusion services company, focused on providing complex pharmaceutical products and clinical services to ...
    ... ... Gets Improvements in Global Content, Search Algorithms, and Analysis Tools , ... Boston, MA (Vocus) May 24, 2010 ... IP -- the latest version of its online IP sequence search product. , ...
    ... researchers find , MONDAY, May 24 (HealthDay News) -- ... a choir could be just what the doctor ordered, ... of relaxation commonly associated with choir participation might actually ... disorder, at least in the short-run, study author Christina ...
    ... ... While Minimizing the Need for Extensive Healing and Recovery Time , ... Los Angeles, Calif. (PRWEB) May 24, ... considering aesthetic procedures is, “How long will it take to heal and recover?” For ...
    Cached Medicine News:Health News:Fewer Sugary Drinks, Less High Blood Pressure 2Health News:Fewer Sugary Drinks, Less High Blood Pressure 3Health News:Prize4Life hosts “Art, Life, Spring” gala and auction to support fight against ALS/Lou Gehrig's Disease 2Health News:Prize4Life hosts “Art, Life, Spring” gala and auction to support fight against ALS/Lou Gehrig's Disease 3Health News:Greater Philadelphia Chamber Welcomes Pentec Health, Incorporated as New Member 2Health News:Greater Philadelphia Chamber Welcomes Pentec Health, Incorporated as New Member 3Health News:GenomeQuest Upgrades Online Patent Searching 2Health News:GenomeQuest Upgrades Online Patent Searching 3Health News:Choir Singing May Relieve Irritable Bowel Syndrome 2Health News:New Laser Treatment Offers Revolutionary Response to Aesthetic Procedure Candidates' Number One Concern: Recovery Time 2
    ... complete imaging access, with nearly 100 percent ... imaging C-Arms can pan from head to ... patient. Anesthesiologists will appreciate this table for ... construction, and ease of operation. The key ...
    ...
    LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
    Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
    Medicine Products: